Appili Therapeutics Commences Trading on the OTCQX Marketplace
15 Junho 2020 - 8:17AM
Business Wire
Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the
“Company” or “Appili”) is pleased to announce today that its common
shares began trading on the OTCQX Best Market®. The OTCQX Market
offers companies efficient, cost-effective access to the U.S.
capital markets. Appili’s shares are trading under the ticker
symbol “APLIF.”
“The OTCQX qualification provides trading access for our
securities to US-based investors, which is an important milestone
as we advance our anti-infective programs and build our visibility
in the global marketplace,” said Kimberly Stephens, CP, CFA, Chief
Financial Officer, Appili Therapeutics. “Our pipeline programs,
including our recently announced trial that is investigating the
use of favipiravir in COVID-19, have implications worldwide. This
milestone provides transparency to our current and future
shareholders on a recognized U.S. securities trading platform.”
The OTCQX® Best Market is for established, investor-focused U.S.
and international companies. To qualify for the OTCQX market,
companies must meet high financial standards, follow best practice
corporate governance, demonstrate compliance with U.S. securities
laws, be current in their disclosure, and have a professional
third-party sponsor introduction.
About Appili Therapeutics
Appili Therapeutics Inc. was founded to advance the global fight
against infectious disease by matching clearly defined patient
needs with drug development programs that provide solutions to
existing challenges patients, doctors, and society face in this
critical disease space. Appili has built a pipeline of assets
designed to address a broad range of significant unmet medical
needs in the infectious disease landscape. This diverse pipeline
aims to address some of the most urgent threats in global public
health, including ATI-2307, a novel, broad spectrum, clinical-stage
antifungal candidate in development for severe and
difficult-to-treat invasive fungal infections; ATI-1701, a vaccine
candidate for tularemia, a very serious biological weapons threat;
ATI-1503, a drug discovery program aimed at generating a novel
class of antibiotics with broad-spectrum activity against
Gram-negative superbugs; and ATI-1501, which employs Appili’s
proprietary, taste-masked, oral-suspension technology with
metronidazole for the growing number of patients with difficulty
swallowing. In addition, the Company is also testing FUJIFILM
Toyama Chemical Inc.’s drug favipiravir for the prevention of
COVID-19 as a potential prophylaxis treatment. Headquartered in
Halifax, Nova Scotia, with offices in Toronto, Ontario, Appili is
pursuing worldwide opportunities in collaboration with scientific
and industry commercial partners, governments and government
agencies. For more information, visit www.AppiliTherapeutics.com.
Forward looking statements This news release contains
“forward-looking statements” which reflect the current expectations
of the Company’s management for future growth, results of
operations, performance and business prospects and opportunities.
Wherever possible, words such as “may “, “would “, “could “,
“should”, “will,” “anticipate,” “believe,” “plan,” “expect,”
“intend,” “estimate,” “potential for” and similar expressions have
been used to identify these forward-looking statements.
Forward-looking statements involve significant known and unknown
risks, uncertainties and assumptions, including, without
limitation, those listed in the annual information form of the
Company dated July 3, 2019 and the other filings made by the
Company with the Canadian securities’ regulatory authorities (which
may be viewed at www.sedar.com). Should one or more of these risks
or uncertainties materialize or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. These factors should be considered carefully,
and prospective investors should not place undue reliance on the
forward-looking statements. The Company disclaims any intention or
obligation to revise forward-looking statements whether as a result
of new information, future developments or otherwise, except as
required by law.
Neither the TSX Venture Exchange, nor its regulation services
provider (as that term is defined in the policies of the exchange),
accepts responsibility for the adequacy or accuracy of this
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200615005157/en/
Media Relations Contact: Andrea Cohen Sam Brown Inc. T:
917-209-7163 E: andreacohen@sambrown.com
Investor Relations Contact: Kimberly Stephens, CFO Appili
Therapeutics Inc. TSXV: APLI E: Info@AppiliTherapeutics.com
Appili Therapeutics (TSXV:APLI)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Appili Therapeutics (TSXV:APLI)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024